Patients with PID disorders are born without some of the body’s immune defenses or with an immune system that is not working properly.
These people suffer more frequent, longer lasting or difficult to treat infections than the infections suffered by people with a normal immune system.
Most PIDs present in childhood although they can manifest at any age, with many inherited primary immunodeficiency disorders.
In an article published by the Fundación JOSEP CARRERAS with information provided, among various sources, by the Barcelona PID Foundation, it is stated that:
“At present, more than 350 PIDs have been described, of which the genetic defect is known in more than 250.The current classification was carried out by an international committee of experts, International Union of Immunology Societies (IUIS), which at its last biennal meeting (2017) grouped the PIDs into 9 groups.
The treatment of patients with PID is divided into the so-called supportive treatment and the curative treatment.”
As a component of supportive treatment, we can highlight replacement therapy with immunoglobulins (Igs), produced from human donor plasma, which can be administered intravenously or subcutaneously, with the possibility of adjusting the volume for each patient, depending on the pharmacokinetics, tolerability and clinical response.
Advances in this field of Igs replacement seek to provide more robust solutions for patients with PID disorders, especially as regards to self-administration at home, using individual ambulatory infusion pumps, increasingly sophisticated and easy to use.
These solutions are hopeful for the thousands of patients suffering from these immune disorders.